Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
4,700
Employees4,700
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
4,700
Employees4,700

MRNA Key Statistics

Market cap
26.70B
Market cap26.70B
Price-Earnings ratio
-8.26
Price-Earnings ratio-8.26
Dividend yield
Dividend yield
Average volume
10.91M
Average volume10.91M
High today
$69.25
High today$69.25
Low today
$59.00
Low today$59.00
Open price
$59.71
Open price$59.71
Volume
14.46M
Volume14.46M
52 Week high
$69.29
52 Week high$69.29
52 Week low
$22.28
52 Week low$22.28

Stock Snapshot

With a market cap of 26.7B, Moderna(MRNA) trades at $67.19. The stock has a price-to-earnings ratio of -8.26.

On 2026-06-29, Moderna(MRNA) stock traded between a low of $59.00 and a high of $69.25. Shares are currently priced at $67.19, which is +13.9% above the low and -3.0% below the high.

Moderna(MRNA) shares are trading with a volume of 14.46M, against a daily average of 10.91M.

In the last year, Moderna(MRNA) shares hit a 52-week high of $69.29 and a 52-week low of $22.28.

In the last year, Moderna(MRNA) shares hit a 52-week high of $69.29 and a 52-week low of $22.28.

MRNA News

Simply Wall St 20h
Moderna Stock and Healthcare Names Facing the Biggest Regulatory Calls

Healthcare regulation is back in focus, and sudden shifts in approvals, safety reviews, and policy debates are putting a spotlight on companies that live and br...

Moderna Stock and Healthcare Names Facing the Biggest Regulatory Calls
TipRanks 2d
Moderna’s Surprise Surge: Is the mRNA Giant Back?

Moderna ( (MRNA) ) has risen by 13.36%. Read on to learn why. TipRanks' Prime Week Sale - 70% Off Unlock powerful investing tools and data-driven insights with...

The Wall Street Journal 2d
Moderna Shares Up on New Research Efforts for Autoimmune Disorder - WSJ

...

Moderna Shares Up on New Research Efforts for Autoimmune Disorder - WSJ

Analyst ratings

67%

of 27 ratings
Buy
14.8%
Hold
66.7%
Sell
18.5%

More MRNA News

Seeking Alpha 2d
Moderna stock soars 15% as bulls cheer drug pipeline update: Next stop $75?

Moderna (MRNA) shares surged nearly ~15% on Friday to around ~$69 and are now up almost ~42% over the past month. The stock has also crushed the S&P 500 (SP500...

Moderna stock soars 15% as bulls cheer drug pipeline update: Next stop $75?
TipRanks 3d
Moderna rises 14.2%

Moderna (MRNA) is up 14.2%, or $8.48 to $68.23. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment de...

Barron's 3d
Why Moderna Stock Is Soaring and Leading the S&P 500 Today

Biotech and Pharma Why Moderna Stock Is Soaring and Leading the S&P 500 Today In this article MRNA SPX LLY Moderna stock was on pace for its highest close since...

Why Moderna Stock Is Soaring and Leading the S&P 500 Today
TipRanks 3d
Hold Rating Reiterated on Moderna as Analyst Keeps $49 Price Target Amid Long-Term Pipeline Potential and Near-Term Execution Risks

In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Hold rating on Moderna, with a price target of $49.00. Unlock powerful investin...

TipRanks 3d
Hold Rating Reaffirmed on Moderna as Analyst Highlights High-Risk/High-Reward Pipeline and Keeps Price Target Unchanged at $41

Analyst Geoff Meacham from Citi maintained a Hold rating on Moderna and keeping the price target at $41.00. TipRanks' Prime Week Sale - 70% Off Unlock powerful...

TipRanks 3d
Analyst Maintains Sell on Moderna as Shares Trade Above Unchanged $34 Price Target Despite Scientific Momentum

Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Moderna yesterday and set a price target of $34.00. Unlock powerful investing too...

Nasdaq 3d
This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst

Key Points Moderna has crushed the market this year, partly thanks to progress related to its flu vaccine. The company should earn approval for this product w...

This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.